Axsome Therapeutics is showcasing Auvelity at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
Auvelity is Axsome's commercial centerpiece — first oral NMDA mechanism for MDD, positioned as a differentiated antidepressant. At APA 2026, the AD agitation FDA decision (April 30) will have JUST happened — if approved, this will dominate their booth messaging. For psychiatrists, the dual MDD + agitation story makes Auvelity a versatile tool in their toolkit.
Ask about: AD agitation approval status (decision literally weeks before conference); Auvelity MDD real-world prescribing data; how they see Auvelity fitting into treatment algorithms vs. SSRIs, SNRIs, and adjunctive atypicals; rapid onset of action data. If AD agitation is approved, ask about launch strategy and how they'll educate psychiatrists who manage agitation in memory care settings.
If AD agitation is approved, VoiceVitals' agitation detection through vocal/facial biomarkers becomes directly relevant for post-market RWE — psychiatrists need objective tools to measure agitation severity in Alzheimer's patients who can't self-report reliably. For MDD, ePRO+ captures Auvelity treatment response trajectories between visits. Position ePRO+ as the outcomes measurement platform for both indications.
Set up a follow-up with Axsome Therapeutics's team and Videra Health.
Email Ryan Roberts →